Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q1 FY27 Earnings Presentation
12 slides from Glenmark Pharmaceuticals's earnings presentation, Jul 31, 2026
Slide 1: Investor Presentation Q1 FY27
Investor Presentation Q1 FY27 31 July 2026
Slide 2: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 3: Summary – Q1 FY27
Summary – Q1 FY27 “We have started FY27 with broad-based growth across our key Consolidated • Consolidated Revenue of Rs. 40,185 million markets, reflecting strong execution and the resilience of our Revenue • YoY growth of 23.1% business. India continued to outperform the market, North America deli
Slide 4: Consolidated Revenue – Q1 FY27
Consolidated Revenue – Q1 FY27 First Quarter ended June 30 Rs. million FY 2027 FY 2026 YoY Growth India 14,321 12,399 15.5% North America # 10,974 7,780 41.1% Europe 7,472 6,678 11.9% Emerging Markets ## 7,304 5,721 27.7% Total 40,071 32,578 23.0% Other Revenue 114 66 72.4% Consolidated Revenue 40,1
Slide 5: India
India Significant outperformance compared to IPM in terms of secondary sales Revenue (Rs. million) YoY: 15.5% Continues to be top-ranked in its core therapeutic areas 14,321 12,399 New launches in Respiratory & Oncology continue to gain scale Q1 FY27 Q1 FY26 Continued strong growth in Glenmark Consu
Slide 6: North America
North America Launched 9 new products in Q1 FY27 Revenue (Rs. million)# First generic approval of FloVent® HFA 44 mcg YoY: 41.1% with 180-day CGT exclusivity 10,974 7,780 Fluticasone Nasal Spray [OTC] launched, three additional Respiratory ANDAs filed earlier Initiated commercialization of RYALTRIS®
Slide 7: Europe
Europe Continued strong growth in branded markets / products Revenue (Rs. million) YoY: 11.9% Increasing contribution from Branded portfolio across Respiratory and Dermatology 7,472 6,678 RYALTRIS® continues to gain market share across the region; additional 8 products launched Q1 FY27 Q1 FY26 Expan
Slide 8: Emerging Markets
Emerging Markets Continued outperformance in Russia Dermatology market Revenue (Rs. million) Very strong secondary sales growth in LATAM YoY: 22.1% and MEA markets 7,304 5,721 Respiratory portfolio continues out- performance in the covered market RYALTRIS® continues to be the leading nasal spray in
Slide 9: Global Innovative Portfolio Update
Global Innovative Portfolio Update QiNHAYO™ TRASTUZUMAB RYALTRIS® WINLEVI® (ENVAFOLIMAB) REZETECAN AUMOLERTINIB • Commercialized in • Launched in • Marketing • First wave of MA • Submitted MA 57 markets several EU authorization applications to applications in 13 markets – applications filed begin Q2
Slide 10: Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases
Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases ONCOLOGY ASSET DESCRIPTION INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS CD38 x BCMA x CD3 ISB 2001 (ABBV-2001) Trispecific Multiple Myeloma T-cell engager Multispecific immune
Slide 11: IGI - Key updates
IGI - Key updates • ISB 2001/ABBV-2001 o To date, >160 subjects have been dosed in the TRIgnite 1 Phase 1 study (42 in dose escalation and >120 in dose expansion) o Safety and efficacy data from all subjects continue to be promising and are consistent with the data previously presented at ASCO 2025
Slide 12: Thank you
G glenmark A new way for a new world
Glenmark Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix